This gene-based therapeutics stock could nearly triple, analysts say
Three firms initiated coverage of the the gene-based therapeutics company.
We haven't written up this one. CNBC has the full story — the link below goes straight to it.
More in Finance & Markets
Australian Dollar remains resilient near two-month high ahead of Fed Minutes
AUD/USD edges higher on Tuesday and trades around 0.7115 at the time of writing, up 0.1% on the day.
U.S. investors have been buying stocks all month and are now sitting on profits. Here’s what might make them sell.
Given that investors are sitting on unrealized gains and there few short positions remain open, the markets are more vulnerable to a downturn in economic news flow.
U.S. investors have been buying stocks all month and are now sitting on profits. Here’s what might make them sell.
Given that investors are sitting on unrealized gains and there few short positions remain open, the markets are more vulnerable to a downturn in economic news flow.
CNN slams White House for personal attacks on reporter over question on Trump aide
“We stand firmly behind @KristenhCNN and reject these attacks in the strongest possible terms,” CNN said in a statement.
DPP approves prosecution of treasury officials over Ksh1.5B misappropriation
The Director of Public Prosecutions (DPP) has approved the prosecution of nine individuals, including three National Treasury officials, over the misappropriation of Ksh1.569 billion under the…
Kalshi seeks to launch ‘perps’ on equity indexes as it moves in on traditional exchanges' turf
The company is seeking to launch a "US500" perp tied to the MerQube U.S. Large Cap Index, according to a regulatory filing.